COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

https://sapiencetherapeutics.com/

---

CAREER WEBSITE

https://sapiencetherapeutics.com/careers/

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Jun 13, 2023

Sapience Therapeutics Announces First Patient Dosed in Phase 1-2 Clinical Study of its First-in-Class β-catenin Antagonist, ST316, in Advanced Solid Tumors

May 4, 2023

Sapience Therapeutics Awarded $2 Million Grant to Evaluate the Therapeutic Potential of ST316, a First-in-Class β-catenin Antagonist

Apr 14, 2023

Sapience Therapeutics to Present Late-Breaking Data on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023

Apr 5, 2023

Sapience Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

Mar 16, 2023

Sapience Therapeutics Announces Late-Breaking Research Poster Presentations on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023

For More Press Releases

---